...
首页> 外文期刊>Bioorganic and medicinal chemistry >Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs
【24h】

Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs

机译:NO供体依达拉奉新药的合成理化特性及PAMPA研究

获取原文
获取原文并翻译 | 示例
           

摘要

A new class of co-drugs were synthesised by joining antioxidant edaravone with a vasodilating substructure containing NO-donor nitrooxy functions, and characterised for their stability in different media, lipophilicity and permeability profile. The products display good stability in water/co-solvent at different pH. Conversely, they are rapidly metabolised into edaravone and NO-donor moieties when incubated in human serum or rat-liver homogenates. In the latter conditions time dependent production of nitriteitrate (NO x) occurs. The compounds display wide-ranging lipophilicity. PAMPA studies predict good gastrointestinal absorption for a number of these compounds. The title products are potentially useful for treating ROS-related conditions accompanied by decreased NO availability.
机译:通过将抗氧化剂依达拉奉与含有NO供体硝基氧基官能团的血管舒张亚结构连接起来,合成了一类新型的共同药物,并表征了它们在不同介质中的稳定性,亲脂性和渗透性。该产品在不同pH值的水/助溶剂中显示出良好的稳定性。相反,当在人血清或大鼠肝脏匀浆中孵育时,它们会迅速代谢成依达拉奉和NO供体部分。在后一种条件下,会产生时间依赖性的亚硝酸盐/硝酸盐(NO x)生成。这些化合物表现出广泛的亲脂性。 PAMPA研究预测许多这类化合物的胃肠道吸收良好。标题产品可能用于治疗与ROS有关的疾病,并伴有NO有效性降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号